

Special Issue

Carbapenem-Resistant Enterobacteriaceae: Epidemiology, Detection and Treatment

Message from the Guest Editor

Enterobacteriaceae are a group of bacteria (germs) that are a normal part of the human and animal gut, but they can also cause infections. Carbapenem-resistant Enterobacteriaceae (CRE) are germs resistant to one or several carbapenem antibiotics. Infections caused by CRE have limited treatment options and are associated with a high mortality rate. This Special Issue welcomes all submissions related to carbapenem-resistant Enterobacteriaceae and aims to develop more effective antibiotic stewardship and infection control measures, promote advances in the treatment of carbapenem-resistant Enterobacteriaceae, and prevent the further spread of carbapenem resistance in Enterobacteriaceae.

Guest Editor

Dr. Seung Soon Lee

Division of Infectious Diseases, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea

Deadline for manuscript submissions

closed (20 May 2025)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



mdpi.com/si/224470

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)